Increased survivin mRNA in malignant pleural effusion is significantly correlated with survival

Japanese Journal of Clinical Oncology
Chou-Chin LanThomas Chang-Yao Tsao

Abstract

The sensitivity of cytologic examination of pleural effusions is variable and not predictive of prognosis. Survivin is an inhibitor of apoptosis that may be a novel diagnostic/prognostic marker of cancers. This study aimed to determine the diagnostic and prognostic value of measuring survivin mRNA levels in pleural effusions. Eighty-eight consecutive pleural effusion samples were examined for both cytology and survivin mRNA level. The accuracy of diagnosis and the correlation between survivin mRNA level and survival in malignant pleural effusion (MPE) were determined. Pleural effusions were divided into three groups: Group I, malignancy-associated (n = 44); Group II, inflammatory (n = 27); and Group III, transudative (n = 17). Survivin mRNA levels in Group I (1.03 +/- 0.61, range 0-2.96) were significantly higher than those in Groups II (0.45 +/- 0.69, range 0-3.30) and III (0.08 +/- 0.22, range 0-0.71) (P < 0.001). Survivin mRNA level was significantly higher in MPE than in non-MPE. The cut-off value for survivin mRNA levels in pleural effusions was 0.074 for the diagnosis of malignancies, with sensitivity, specificity, and positive and negative predictive values of 96%, 45%, 45% and 96%, respectively. Survivin mRNA level in p...Continue Reading

References

Aug 1, 1997·Nature Medicine·G AmbrosiniD C Altieri
Jun 3, 1999·Diagnostic Cytopathology·H MotherbyA Böcking
Mar 29, 2000·Archives of Internal Medicine·A ViganóM E Suarez-Almazor
Nov 9, 2000·American Journal of Respiratory and Critical Care Medicine·UNKNOWN American Thoracic Society
Feb 15, 2001·JAMA : the Journal of the American Medical Association·S D SmithD C Altieri
Aug 21, 2001·Journal of Insurance Medicine·M Moore
Jun 4, 2002·Nature Reviews. Molecular Cell Biology·Guy S Salvesen, Colin S Duckett
Sep 13, 2002·Chest·Michael D BrundageWilliam J Mackillop
Jan 2, 2003·Nature Reviews. Cancer·Dario C Altieri
Aug 5, 2003·The Journal of Pathology·Monica FalleniSilvano Bosari
May 19, 2004·The Journal of Experimental Medicine·Frank AltznauerHans-Uwe Simon
Apr 15, 2005·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Monica FalleniSilvano Bosari
Mar 14, 2007·Human Pathology·Lilach KleinbergBen Davidson

❮ Previous
Next ❯

Citations

Jun 15, 2012·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Jian LiPing Chen
Mar 26, 2011·Pathology·Steven Chuan-Hao KaoSonja Klebe
Jun 25, 2013·Respiratory Medicine·Didem GörgünPınar Yıldız
Jan 7, 2015·Clinica Chimica Acta; International Journal of Clinical Chemistry·Shi ChenTian Li
Mar 17, 2015·Mutation Research·Ombretta MelaiuStefano Landi
Jan 24, 2018·European Journal of Clinical Investigation·Elena Arellano-OrdenRemedios Otero-Candelera
Jan 30, 2013·Virchows Archiv : an International Journal of Pathology·Julija HmeljakAndrej Cör
Aug 30, 2012·International Journal of Cancer. Journal International Du Cancer·Jian LiLi-Ping Ge

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.